# EDGAR Filing Document

**Accession Number:** 0000275053
**File Stem:** 0001140361-25-023972
**Filing Date:** 2025-6
**Character Count:** 22391
**Document Hash:** e123f1e3b74286048fc7bb38e7cd5afc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-023972.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001140361-25-023972

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NATURES SUNSHINE PRODUCTS INC
- **CENTRAL INDEX KEY:** 0000275053
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870327982
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-32703
- **FILM NUMBER:** 251086469

**BUSINESS ADDRESS:**
- **STREET 1:** 2901 WEST BLUEGRASS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043
- **BUSINESS PHONE:** (801) 341-7900

**MAIL ADDRESS:**
- **STREET 1:** 2901 WEST BLUEGRASS BLVD.
- **STREET 2:** SUITE 100
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMTEC INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19821108
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- **CENTRAL INDEX KEY:** 0001615258

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING A
- **STREET 2:** NO. 1289 YISHAN ROAD
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200233
- **BUSINESS PHONE:** 86 21 33987870

**MAIL ADDRESS:**
- **STREET 1:** BUILDING A
- **STREET 2:** NO. 1289 YISHAN ROAD
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200233

## Exhibit 99.1

------

#### Exhibit 99.1

#### DIRECTORS AND EXECUTIVE OFFICERS OF FOSUN PHARMA PERSONS CONTROLLING FOSUN

#### PHARMA AND EXECUTIVE OFFICERS AND DIRECTORS OF OTHER PERSONS IN CONTROL OF

#### FOSUN PHARMA, FPUSA AND FOSUN INDUSTRIAL

Fosun Pharma is a corporation organized under the laws of the People's Republic of China and listed on both the Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited with its principal business address at Building A, No. 1289 Yishan Road Shanghai, 200233, China. Fosun Pharma is an innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Pharma is set forth below.

#### Fosun Pharma

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal Employment** | **Citizenship** |
| Chen Yuqing | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Chairman of the Board of Directors | China |
| Guan Xiaohui | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Co-Chairman of the Board of Directors | China |
| Wen Deyong | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director, Deputy Chairman of the Board of Directors, Chief Executive Officer | China |
| Wang Kexin | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Executive Director | China |
| Chen Qiyu | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | China |
| Pan Donghui | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | Hong Kong, China |
| Wu Yifang | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Non-executive Director | China |
| Yu Tze Shan Hailson | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | Hong Kong, China |
| Wang Quandi | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | China |
| Chen Penghui | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | United States |
| Yang Yucheng | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Independent Non-executive Director | China |
| Yan Jia | Building A, No. 1289 Yishan Road Shanghai, 200233, China | Employee Director | China |

---

------

Fosun Pharma is a subsidiary of Fosun High Technology. Fosun High Technology is a corporation organized under the laws of the People's Republic of China with its principal business address at 16<sup>th</sup> Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China. Fosun High Technology is a subsidiary of Fosun International, which is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun High Technology is set forth below.

#### Fosun High Technology

---

| | | |
|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** |
| Chen Qiyu | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Chairman of the Board of Directors<br> China |
| Xu Xiaoliang | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Director and general manager<br> China |
| Gong Ping | 16th Floor, Tower S1, 600 Zhongshan No. 2 Road (E), Shanghai, Huangpu District, Shanghai, China | Director<br> China |

---

Fosun High Technology is a subsidiary of Fosun International. Fosun International is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International's ordinary shares are listed on the main board of The Stock Exchange of Hong Kong Limited. Fosun International is a global innovation-driven consumer group which operates in four business segments, namely health, happiness, wealth and intelligent manufacturing.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International is set forth below.

#### Fosun International

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Chairman | Hong Kong, China |
| WANG Qunbin | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chairman | Hong Kong, China |
| CHEN Qiyu | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chief Executive Officer | China |
| XU Xiaoliang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Co-Chief Executive Officer | China |
| GONG Ping | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director, Executive President and Chief Financial Officer | China |
| HUANG Zhen | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director and Executive President | China |
| PAN Donghui | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Executive Director, Executive President and Chief Human Resources Officer | Hong Kong, China |
| LI Shupei | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Non-executive Director | China |
| LI Fuhua | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Non-executive Director | China |
| Luo Yuanli | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Non-executive Director | China |
| ZHANG Shengman | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| ZHANG Huaqiao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| David T. ZHANG | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |
| LEE Kai-Fu | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Republic of China |
| TSANG King Suen Katherine | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Independent Non-executive Director | Hong Kong, China |

---

------

Fosun International is a subsidiary of Fosun Holdings. Fosun Holdings is a corporation organized under the laws of Hong Kong with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Holdings is set forth below.

#### Fosun Holdings

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal** <br> **Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LAW Tsz Kwan Iris | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LI Tao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |

---

Fosun Holdings is a subsidiary of Fosun International Holdings. Fosun International Holdings is a corporation organized under the laws of British Virgin Islands with its principal business address at Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. Fosun International Holdings is principally engaged in investment holding.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun International Holdings is set forth below.

#### Fosun International Holdings

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business Address** | **Present Principal**<br> **Employment** | **Citizenship** |
| GUO Guangchang | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LAW Tsz Kwan Iris | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |
| LI Tao | Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong | Director | Hong Kong, China |

---

------

Fosun International Holdings is owned 82.59% by Guangchang Guo with the remaining shares owned 17.41% by Qunbin Wang. Guangchang Guo's principal business address is Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. He is a citizen of Hong Kong, China.

The name, business address, present principal employment and citizenship of each director and executive officer of FPUSA is set forth below.

#### Fosun Pharma USA Inc.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal** <br> **Employment** | **Citizenship** |
| Wu Yifang | 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | China |
| Zhang Wenjie | 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | US Citizen |
| Feng Rongli | 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540 | Director | China |

---

FPUSA is a wholly owned subsidiary of Fosun Pharma. FPUSA is a Delaware corporation. Its principal place of business is 104 Carnegie Center Drive, Suite 204, Princeton, New Jersey 08540. FPUSA is a specialty pharmaceutical company.

The name, business address, present principal employment and citizenship of each director and executive officer of Fosun Industrial is set forth below.

#### Fosun Industrial

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Business address** | **Present Principal Employment** | **Citizenship** |
| Guan Xiaohui | Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong | Chairman of the Board of Director | China |
| LAW Tsz Kwan Iris | Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong | Director | Hong Kong, China |
| HUNG HSIU YING SAMMI | Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong | Director | Hong Kong, China |

---

Fosun Industrial is a wholly owned subsidiary of Fosun Pharma. The address of the principal business office for Fosun Industrial is Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. Fosun Industrial is a company incorporated under the laws of Hong Kong. Fosun Industrial is principally engaged in foreign investment, sale and consultancy service of Chinese and western medicine, diagnostic reagent, medical device products and relevant import and export business.

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**NATURES SUNSHINE PRODUCTS INC**

*(Name of Issuer)*

**Common Stock, no par value**

*(Title of Class of Securities)*

**639027101**

*(CUSIP Number)*

**Yuqing Chen**<br>Shanghai Fosun Pharmaceutical (Group) Co<br>Ltd., No.1289 Yishan Road<br>Shanghai F4 200233<br>86 (21) 33987000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **639027101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.** | Name of reporting person<br>**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CHINA** | Citizenship or place of organization<br>**CHINA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**64167.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**64167.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**64167.00** | Aggregate amount beneficially owned by each reporting person<br>**64167.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.35%** | Percent of class represented by amount in Row (11)<br>**0.35%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **639027101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fosun Pharma USA Inc.** | Name of reporting person<br>**Fosun Pharma USA Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, no par value

**(b) Name of Issuer:**
NATURES SUNSHINE PRODUCTS INC

**(c) Address of Issuer's Principal Executive Offices:**
2901 West Bluegrass Blvd., Suite 100, Lehi, UT, 84043

This Amendment No. 3 amends, as set forth below, the Schedule 13D originally filed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") with the Securities and Exchange Commission ("SEC") on August 4, 2014, as amended by Amendment No. 1 ("Amendment No. 1") filed with the SEC on September 2, 2014, as further amended by Amendment No. 2 ("Amendment No. 2") filed with the SEC on June 9, 2025 (the "Original Schedule 13D," and together with Amendment No. 1, Amendment No. 2, and this Amendment No. 3, the "Schedule 13D") relating to the Common Stock of the Issuer. Fosun Pharma and Fosun Pharma USA Inc. ("FPUSA") are referred to herein collectively as the "Reporting Persons."

**Item 4. Purpose of Transaction**

Item 4 is hereby amended by adding the following paragraphs:

On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of 2,854,607 shares of Common Stock (the "Shares"), being sold by FPUSA at a public offering price of $12.00 per share (the "Offering"), less the underwriting discounts and commissions of $0.54 per share, resulting in net proceeds to FPUSA of $11.46 per share. The Offering closed on June 27, 2025. The Offering was made pursuant to the Issuer's shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed with the SEC on June 9, 2025 and became effective on June 18, 2025. The base prospectus included in the registration statement, was amended and supplemented by the preliminary prospectus supplement filed with the SEC on June 25, 2025, and the final prospectus supplement filed with the SEC on June 27, 2025.

Pursuant to the Underwriting Agreement, FPUSA has entered into a lock-up agreement (the "Lock-Up Agreement") pursuant to which FPUSA has agreed not to sell or transfer any securities of the Issuer held by it for a period of 90 days from June 27, 2025, subject to limited exceptions.

In connection with the Offering, FPUSA entered into a share repurchase agreement (the "Share Repurchase Agreement") with the Issuer, pursuant to which the Issuer agreed that it may purchase up to $15.0 million of the shares of the Issuer's Common Stock that are subject to the Offering from the Underwriter at the public offering price as part of its previously announced share repurchase program.

The descriptions of the Underwriting Agreement, Lock-up Agreement, and Share Repurchase Agreement contained in this Item 4 are not intended to be complete and are qualified in their entirety by reference to the Underwriting Agreement, Form of Lock-Up Agreement and Share Repurchase Agreement, each of which is filed as an exhibit hereto and incorporated by reference herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of the Reporting Persons to Rows (7) through (11), and (13) of the cover pages of this Amendment No. 3 are incorporated herein by reference. Fosun Pharma beneficially owns an aggregate of 64,167 shares of Common Stock. This amount consists of 64,167 shares of Common Stock held directly by Fosun Industrial Co., Limited. The aggregate percentage of shares of Common Stock reported as beneficially owned by Fosun Pharma was calculated based on 18,463,179 shares of Common Stock issued and outstanding as of June 9, 2025, as disclosed in the Issuer's prospectus supplement filed with the SEC on June 27, 2025, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended.

**(b)**
See Item 5(a).

**(c)**
Except for the sale of 2,854,607 shares of Common Stock in the Offering pursuant to the Underwriting Agreement, none of the Reporting Persons have effected any transaction in the Common Stock since Amendment No. 2.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended by adding the following paragraph:

The descriptions of the Underwriting Agreement, Lock-Up Agreement and Share Repurchase Agreement included in Item 4 above is incorporated by reference into this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

**Signature:** /s/ Yuqing Chen

**Name/Title:** Yuqing Chen / Chairman

**Date:** 06/27/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fosun Pharma USA Inc.

**Signature:** /s/ Yuqing Wang

**Name/Title:** Yuqing Wang / Chief Financial Officer

**Date:** 06/27/2025